Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - linezolid (form iii) - film coated tablet - 600 milligram - linezolid - antibacterials for systemic use; other antibacterials - linezolid is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration. (see section 5.1 for the appropriate organisms).

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid is indicated for the treatment of nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and –resistant isolates) or streptococcus pneumoniae [see clinical studies (14)]. linezolid is indicated for the treatment of community-acquired pneumonia caused by streptococcus pneumoniae, including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14)]. linezolid is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes, or streptococcus agalactiae. linezolid has not been studied in the treatment of decubitus ulcers [see clinical studies (14)]. linezolid is indicated for the treatment of uncomplicated skin and skin structure infections caused by staphylococcus aureus (methicillin-susceptible isolates only) or streptococcus pyogenes [see clinical studies (14)]. linezolid is indicated for the treatment of vancomycin-resistant enterococcus faecium infections, including cases with concurrent bacteremia [see clinical studies (14)]. -   linezolid is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4)] -   the safety and efficacy of linezolid formulations given for longer than 28 days have not been evaluated in controlled clinical trials [see clinical studies (14)] to reduce the development of drug-resistant bacteria and maintain the effectiveness of linezolid tablets and other antibacterial drugs, linezolid tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. linezolid formulations are contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components. linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases a or b (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product. risk summary available data from published and postmarketing case reports with linezolid use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. when administered during organogenesis, linezolid did not cause malformations in mice, rats, or rabbits at maternal exposure levels approximately 6.5 times (mice), equivalent to (rats), or 0.06 times (rabbits) the clinical therapeutic exposure, based on aucs. however, embryo-fetal lethality was observed in mice at 6.5 times the estimated human exposure. when female rats were dosed during organogenesis through lactation, postnatal survival of pups was decreased at doses approximately equivalent to the estimated human exposure based on aucs (see data). the background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data in mice, embryo-fetal toxicities were observed only at doses that caused maternal toxicity (clinical signs and reduced body weight gain). an oral dose of 450 mg/kg/day given from gestation day (gd) 6-16 (6.5 times the estimated human exposure based on aucs) correlated with increased postimplantational embryo death, including total litter loss, decreased fetal body weights, and an increased incidence of costal cartilage fusion. neither maternal nor embryo-fetal toxicities were observed at doses up to 150 mg/kg/day. fetal malformations were not observed in rats, fetal toxicity was observed at 15 and 50 mg/kg/day administered orally from gd 6-17 (exposures 0.22 times to approximately equivalent to the estimated human exposure, respectively, based on aucs). the effects consisted of decreased fetal body weights and reduced ossification of sternebrae, a finding often seen in association with decreased fetal body weights. fetal malformations were not observed. maternal toxicity, in the form of reduced body weight gain, was seen at 50 mg/kg/day. in rabbits, reduced fetal body weight occurred only in the presence of maternal toxicity (clinical signs, reduced body weight gain and food consumption) when administered at an oral dose of 15 mg/kg/day given from gd 6-20 (0.06 times the estimated human exposure based on aucs). fetal malformations were not observed. when female rats were treated with 50 mg/kg/day (approximately equivalent to the estimated human exposure based on aucs) of linezolid during pregnancy and lactation (gd 6 through lactation day 20), survival of pups was decreased on postnatal days 1 to 4. male and female pups permitted to mature to reproductive age, when mated, showed an increase in preimplantation loss. risk summary linezolid is present in breast milk. based on data from available published case reports, the daily dose of linezolid that the infant would receive from breastmilk would be approximately 6% to 9% of the recommended therapeutic infant dose (10 mg/kg every 8 hours). there is no information on the effects of linezolid on the breastfed infant; however, diarrhea and vomiting were the most common adverse reactions reported in clinical trials in infants receiving linezolid therapeutically [see adverse reactions (6.1)] and (see clinical considerations). there is no information on the effects of linezolid on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for linezolid and any potential adverse effects on the breastfed child from linezolid or from the underlying maternal condition. clinical considerations advise lactating women to monitor a breastfed infant for diarrhea and vomiting. infertility males based on findings from studies in rats, linezolid may reversibly impair fertility in male patients [see nonclinical toxicology (13.1)]. the safety and effectiveness of linezolid for the treatment of pediatric patients with the following infections are supported by evidence from adequate and well-controlled studies in adults, pharmacokinetic data in pediatric patients, and additional data from a comparator-controlled study of gram-positive infections in pediatric patients ranging in age from birth through 11 years [see indications and usage (1), clinical pharmacology (12.3) and clinical studies (14)] : - nosocomial pneumonia - complicated skin and skin structure infections - community-acquired pneumonia (also supported by evidence from an uncontrolled study in patients ranging in age from 8 months through 12 years) - vancomycin-resistant enterococcus faecium infections the safety and effectiveness of linezolid for the treatment of pediatric patients with the following infection have been established in a comparator-controlled study in pediatric patients ranging in age from 5 through 17 years [see clinical studies (14)] : - uncomplicated skin and skin structure infections caused by staphylococcus aureus (methicillin-susceptible strains only) or streptococcus pyogenes pharmacokinetic information generated in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (csf) linezolid concentrations following single and multiple dosing of linezolid; therapeutic concentrations were not consistently achieved or maintained in the csf. therefore, the use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended. the pharmacokinetics of linezolid have been evaluated in pediatric patients from birth to 17 years of age. in general, weight-based clearance of linezolid gradually decreases with increasing age of pediatric patients. however, in preterm (gestational age < 34 weeks) neonates < 7 days of age, linezolid clearance is often lower than in full-term neonates < 7 days of age. consequently, preterm neonates < 7 days of age may need an alternative linezolid dosing regimen of 10 mg/kg every 12 hours [see dosage and administration (2.1) and clinical pharmacology (12.3)] . in limited clinical experience, 5 out of 6 (83%) pediatric patients with infections due to gram-positive pathogens with minimum inhibitory concentrations (mics) of 4 mcg/ml treated with linezolid had clinical cures. however, pediatric patients exhibit wider variability in linezolid clearance and systemic exposure (auc) compared with adults. in pediatric patients with a sub-optimal clinical response, particularly those with pathogens with mic of 4 mcg/ml, lower systemic exposure, site and severity of infection and the underlying medical condition should be considered when assessing clinical response [see clinical pharmacology (12.3) and dosage and administration (2)] . of the 2,046 patients treated with linezolid in phase 3 comparator-controlled clinical trials, 589 (29%) were 65 years or older and 253 (12%) were 75 years or older. no overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

United States - English - NLM (National Library of Medicine)

piramal critical care inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid injection is indicated for the treatment of nosocomial pneumonia caused by s taphylococcus aureu s (methicillinsusceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies ( 14) ]. linezolid injection is indicated for the treatment of community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies ( 14) ]. linezolid injection is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or streptococcus agalactiae . linezolid injection has not been studied in the treatment of decubitus ulcers [see clinical studies ( 14) ]. linezolid injection is indicated for the treatment of uncomplicated skin and skin structure infections caused by staphylococcus aureus (methicillin-susceptible isolates only) or streptococcus pyogenes [see clinical studies ( 14) ]. linezolid injection is indicated for the treatment of vancomycin-resistant enterococcus faecium infections, including cases with concurrent bacteremia [see clinical studies ( 14) ]. - linezolid injection is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precaution s ( 5.4) ]. - the safety and efficacy of linezolid injection formulations given for longer than 28 days have not been evaluated in controlled clinical trials [see clinical studies ( 14) ]. to reduce the development of drug-resistant bacteria and maintain the effectiveness of linezolid injection and other antibacterial drugs, linezolid injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. linezolid formulations are contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components. linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases a or b (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product. risk summary available data from published and postmarketing case reports with linezolid use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. when administered during organogenesis, linezolid did not cause malformations in mice, rats, or rabbits at maternal exposure levels approximately 6.5 times (mice), equivalent to (rats), or 0.06 times (rabbits) the clinical therapeutic exposure, based on aucs. however, embryo-fetal lethality was observed in mice at 6.5 times the estimated human exposure. when female rats were dosed during organogenesis through lactation, postnatal survival of pups was decreased at doses approximately equivalent to the estimated human exposure based on aucs (see data). the background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data in mice, embryo-fetal toxicities were observed only at doses that caused maternal toxicity (clinical signs and reduced body weight gain). an oral dose of 450 mg/kg/day given from gestation day (gd) 6-16 (6.5 times the estimated human exposure based on aucs) correlated with increased postimplantational embryo death, including total litter loss, decreased fetal body weights, and an increased incidence of costal cartilage fusion. neither maternal nor embryo-fetal toxicities were observed at doses up to 150 mg/kg/day. fetal malformations were not observed. in rats, fetal toxicity was observed at 15 and 50 mg/kg/day administered orally from gd 6-17 (exposures 0.22 times to approximately equivalent to the estimated human exposure, respectively, based on aucs). the effects consisted of decreased fetal body weights and reduced ossification of sternebrae, a finding often seen in association with decreased fetal body weights. fetal malformations were not observed. maternal toxicity, in the form of reduced body weight gain, was seen at 50 mg/kg/day. in rabbits, reduced fetal body weight occurred only in the presence of maternal toxicity (clinical signs, reduced body weight gain and food consumption) when administered at an oral dose of 15 mg/kg/day given from gd 6-20 (0.06 times the estimated human exposure based on aucs). fetal malformations were not observed. when female rats were treated with 50 mg/kg/day (approximately equivalent to the estimated human exposure based on aucs) of linezolid during pregnancy and lactation (gd 6 through lactation day 20), survival of pups was decreased on postnatal days 1 to 4. male and female pups permitted to mature to reproductive age, when mated, showed an increase in preimplantation loss. risk summary linezolid is present in breast milk. based on data from available published case reports, the daily dose of linezolid that the infant would receive from breastmilk would be approximately 6% to 9% of the recommended therapeutic infant dose (10 mg/kg every 8 hours). there is no information on the effects of linezolid on the breastfed infant; however, diarrhea and vomiting were the most common adverse reactions reported in clinical trials in infants receiving linezolid therapeutically [see adverse reactions ( 6.1) ] and (see clinical considerations ). there is no information on the effects of linezolid on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for linezolid and any potential adverse effects on the breastfed child from linezolid or from the underlying maternal condition. clinical considerations advise lactating women to monitor a breastfed infant for diarrhea and vomiting. infertility males based on findings from studies in rats, linezolid may reversibly impair fertility in male patients [see nonclinical toxicology ( 13.1) ]. the safety and effectiveness of linezolid for the treatment of pediatric patients with the following infections are supported by evidence from adequate and well-controlled studies in adults, pharmacokinetic data in pediatric patients, and additional data from a comparator-controlled study of gram-positive infections in pediatric patients ranging in age from birth through 11 years [see indications and usage ( 1), clinical pharmacology ( 12.3) and clinical studies ( 14) ]: • nosocomial pneumonia • complicated skin and skin structure infections • community-acquired pneumonia (also supported by evidence from an uncontrolled study in patients ranging in age from 8 months through 12 years) • vancomycin-resistant enterococcus faecium infections the safety and effectiveness of linezolid for the treatment of pediatric patients with the following infection have been established in a comparator-controlled study in pediatric patients ranging in age from 5 through 17 years [see clinical studies ( 14) ]: • uncomplicated skin and skin structure infections caused by staphylococcus aureus (methicillin-susceptible strains only) or streptococcus pyogenes pharmacokinetic information generated in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (csf) linezolid concentrations following single and multiple dosing of linezolid; therapeutic concentrations were not consistently achieved or maintained in the csf. therefore, the use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended. the pharmacokinetics of linezolid have been evaluated in pediatric patients from birth to 17 years of age. in general, weight-based clearance of linezolid gradually decreases with increasing age of pediatric patients. however, in preterm (gestational age < 34 weeks) neonates < 7 days of age, linezolid clearance is often lower than in full-term neonates < 7 days of age. consequently, preterm neonates < 7 days of age may need an alternative linezolid dosing regimen of 10 mg/kg every 12 hours [see dosage and administration ( 2.1) and clinical pharmacology ( 12.3) ]. in limited clinical experience, 5 out of 6 (83%) pediatric patients with infections due to gram-positive pathogens with minimum inhibitory concentrations (mics) of 4 mcg/ml treated with linezolid had clinical cures. however, pediatric patients exhibit wider variability in linezolid clearance and systemic exposure (auc) compared with adults. in pediatric patients with a sub-optimal clinical response, particularly those with pathogens with mic of 4 mcg/ml, lower systemic exposure, site and severity of infection, and the underlying medical condition should be considered when assessing clinical response [see clinical pharmacology ( 12.3) and dosage and administration ( 2) ]. of the 2,046 patients treated with linezolid in phase 3 comparator-controlled clinical trials, 589 (29%) were 65 years or older and 253 (12%) were 75 years or older. no overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid is indicated for the treatment of nosocomial pneumonia caused by staphylococcus aureus  (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14) ]. linezolid is indicated for the treatment of community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. linezolid is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or streptococcus agalactiae . linezolid has not been studied in the treatment of decubitus ulcers [see clinical studies (14) ]. linezolid is indicated for the treatment of uncomplicated skin and skin structure infections caused by staphylococcus aureus (methicillin-susceptible isolates only) or streptococcus pyogenes [see clinical studies (14) ]. linezolid is indicated for the treatment of vancomycin-resistant enterococcus faecium infections, including cases with concurrent bacteremia [see clinical studies (14) ]. - linezolid is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4) ]. gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4) ]. - the safety and efficacy of linezolid formulations given for longer than 28 days have not been evaluated in controlled clinical trials [see clinical studies (14) ]. to reduce the development of drug-resistant bacteria and maintain the effectiveness of linezolid injection and other antibacterial drugs, linezolid injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. linezolid injection is contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components. linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases a or b (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product. risk summary available data from published and postmarketing case reports with linezolid use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. when administered during organogenesis, linezolid did not cause malformations in mice, rats, or rabbits at maternal exposure levels approximately 6.5 times (mice), equivalent to (rats), or 0.06 times (rabbits) the clinical therapeutic exposure, based on aucs. however, embryo-fetal lethality was observed in mice at 6.5 times the estimated human exposure. when female rats were dosed during organogenesis through lactation, postnatal survival of pups was decreased at doses approximately equivalent to the estimated human exposure based on aucs (see data ). the background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data in mice, embryo-fetal toxicities were observed only at doses that caused maternal toxicity (clinical signs and reduced body weight gain). an oral dose of 450 mg/kg/day given from gestation day (gd) 6 to 16 (6.5 times the estimated human exposure based on aucs) correlated with increased postimplantational embryo death, including total litter loss, decreased fetal body weights, and an increased incidence of costal cartilage fusion. neither maternal nor embryo-fetal toxicities were observed at doses up to 150 mg/kg/day. fetal malformations were not observed. in rats, fetal toxicity was observed at 15 and 50 mg/kg/day administered orally from gd 6 to 17 (exposures 0.22 times to approximately equivalent to the estimated human exposure, respectively, based on aucs). the effects consisted of decreased fetal body weights and reduced ossification of sternebrae, a finding often seen in association with decreased fetal body weights. fetal malformations were not observed. maternal toxicity, in the form of reduced body weight gain, was seen at 50 mg/kg/day. in rabbits, reduced fetal body weight occurred only in the presence of maternal toxicity (clinical signs, reduced body weight gain and food consumption) when administered at an oral dose of 15 mg/kg/day given from gd 6 to 20 (0.06 times the estimated human exposure based on aucs). fetal malformations were not observed. when female rats were treated with 50 mg/kg/day (approximately equivalent to the estimated human exposure based on aucs) of linezolid during pregnancy and lactation (gd 6 through lactation day 20), survival of pups was decreased on postnatal days 1 to 4. male and female pups permitted to mature to reproductive age, when mated, showed an increase in preimplantation loss. risk summary linezolid is present in breast milk. based on data from available published case reports, the daily dose of linezolid that the infant would receive from breastmilk would be approximately 6% to 9% of the recommended therapeutic infant dose (10 mg/kg every 8 hours). there is no information on the effects of linezolid on the breastfed infant; however, diarrhea and vomiting were the most common adverse reactions reported in clinical trials in infants receiving linezolid therapeutically [see adverse reactions (6.1) ] and (see clinical considerations). there is no information on the effects of linezolid on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for linezolid and any potential adverse effects on the breastfed child from linezolid or from the underlying maternal condition. clinical considerations advise lactating women to monitor a breastfed infant for diarrhea and vomiting. infertility males based on findings from studies in rats, linezolid may reversibly impair fertility in male patients [see nonclinical toxicology (13.1) ]. the safety and effectiveness of linezolid for the treatment of pediatric patients with the following infections are supported by evidence from adequate and well-controlled studies in adults, pharmacokinetic data in pediatric patients, and additional data from a comparator-controlled study of gram-positive infections in pediatric patients ranging in age from birth through 11 years [see indications and usage (1),clinical pharmacology (12.3) and clinical studies (14) ]: - ·nosocomial pneumonia - complicated skin and skin structure infections - community-acquired pneumonia (also supported by evidence from an uncontrolled study in patients ranging in age from 8 months through 12 years) - ·vancomycin-resistant enterococcus faecium infections the safety and effectiveness of linezolid for the treatment of pediatric patients with the following infection have been established in a comparator-controlled study in pediatric patients ranging in age from 5 through 17 years [see clinical studies (14) ]: the safety and effectiveness of linezolid for the treatment of pediatric patients with the following infection have been established in a comparator-controlled study in pediatric patients ranging in age from 5 through 17 years [see clinical studies (14) ]: - uncomplicated skin and skin structure infections caused by staphylococcus aureus (methicillin­-susceptible strains only) or streptococcus pyogenes pharmacokinetic information generated in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (csf) linezolid concentrations following single and multiple dosing of linezolid; therapeutic concentrations were not consistently achieved or maintained in the csf. therefore, the use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended. the pharmacokinetics of linezolid have been evaluated in pediatric patients from birth to 17 years of age. in general, weight-based clearance of linezolid gradually decreases with increasing age of pediatric patients. however, in preterm (gestational age < 34 weeks) neonates < 7 days of age, linezolid clearance is often lower than in full-term neonates < 7 days of age. consequently, preterm neonates < 7 days of age may need an alternative linezolid dosing regimen of 10 mg/kg every 12 hours [see dosage and administration (2.1 ) and clinical pharmacology (12.3 )]. in limited clinical experience, 5 out of 6 (83%) pediatric patients with infections due to gram-positive pathogens with minimum inhibitory concentrations (mics) of 4 mcg/ml treated with linezolid had clinical cures. however, pediatric patients exhibit wider variability in linezolid clearance and systemic exposure (auc) compared with adults. in pediatric patients with a sub-optimal clinical response, particularly those with pathogens with mic of 4 mcg/ml, lower systemic exposure, site and severity of infection, and the underlying medical condition should be considered when assessing clinical response [see clinical pharmacology (12.3) and dosage and administration (2) ]. of the 2,046 patients treated with linezolid in phase 3 comparator-controlled clinical trials, 589 (29%) were 65 years or older and 253 (12%) were 75 years or older. no overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: silicon dioxide; sodium stearylfumarate; copovidone; mannitol; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - pharmacor linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,pharmacor linezolid is active against gram-positive bacteria only. pharmacor linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: mannitol; silicon dioxide; copovidone; sodium stearylfumarate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - pharmacor linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,pharmacor linezolid is active against gram-positive bacteria only. pharmacor linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; copovidone; mannitol; silicon dioxide; sodium stearylfumarate; titanium dioxide; hypromellose; macrogol 400 - akm linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,akm linezolid is active against gram-positive bacteria only. akm linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: sodium stearylfumarate; mannitol; pregelatinised maize starch; silicon dioxide; copovidone; titanium dioxide; hypromellose; macrogol 400 - akm linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,akm linezolid is active against gram-positive bacteria only. akm linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - linezolid - solution for infusion - 2 milligram(s)/millilitre - other antibacterials; linezolid - antibacterials for systemic use - linezolid clonmel is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid clonmel is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - linezolid - film-coated tablet - 600 milligram(s) - other antibacterials; linezolid - antibacterials for systemic use, other antibacterials - linezolid krka is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid krka is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration